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Therapeutic strategies based on modulation of
microRNA (miRNA) activity hold great promise due
to the ability of these small RNAs to potently influ-
ence cellular behavior. In this study, we investigated
the efficacy of a miRNA replacement therapy for
liver cancer. We demonstrate that hepatocellular
carcinoma (HCC) cells exhibit reduced expression
of miR-26a, a miRNA that is normally expressed at
high levels in diverse tissues. Expression of this
miRNA in liver cancer cells in vitro induces cell-cycle
arrest associated with direct targeting of cyclins D2
and E2. Systemic administration of this miRNA in a
mouse model of HCC using adeno-associated virus
(AAV) results in inhibition of cancer cell proliferation,
induction of tumor-specific apoptosis, and dramatic
protection from disease progression without toxicity.
These findings suggest that delivery of miRNAs that
are highly expressed and therefore tolerated in
normal tissues but lost in disease cells may provide
a general strategy for miRNA replacement therapies.
INTRODUCTION
MicroRNAs (miRNAs) are a diverse class of highly conserved
small RNA molecules that function as critical regulators of gene
expression in multicellular eukaryotes and some unicellular
eukaryotes (Kato and Slack, 2008). miRNAs are initially tran-
scribed as long primary transcripts (pri-miRNAs) that undergo
sequential processing by the RNase III endonucleases Drosha
and Dicer to yield the mature 20–23 nucleotide species (Kim,2005). Mature miRNAs associate with the RNA-induced silencing
complex (RISC) and interact with sites of imperfect complemen-
tarity in 30 untranslated regions (UTRs) of target mRNAs. Targeted
transcripts subsequently undergo accelerated turnover and
translational repression (Valencia-Sanchez et al., 2006). Impor-
tantly, the ability of individual miRNAs to regulate hundreds of
transcripts allows these RNAs to coordinate complex programs
of gene expression and thereby induce global changes in cellular
physiology. Indeed, a growing body of evidence has documented
that miRNAs provide functions essential for normal development
and cellular homeostasis and, accordingly, dysfunction of these
molecules has been linked to several human diseases (Klooster-
man and Plasterk, 2006).
Over the last 5 years, a particularly important role for miRNAs
in cancer pathogenesis has emerged. Virtually all examined
tumor types are characterized by globally abnormal miRNA
expression patterns (Calin and Croce, 2006). Profiles of miRNA
expression are highly informative for tumor classification, prog-
nosis, and response to therapy. Moreover, recent results have
documented a functional contribution of specific miRNAs to
cellular transformation and tumorigenesis. For example, miRNAs
are known targets of genomic lesions that frequently activate
oncogenes and inactivate tumor suppressors in cancer cells,
such as amplification, deletion, and epigenetic silencing (Calin
et al., 2004; Lujambio and Esteller, 2007; Zhang et al., 2006).
Additionally, miRNAs provide critical functions downstream of
classic oncogenic and tumor suppressor signaling pathways
such as those controlled by Myc and p53 (Chang et al., 2008;
He et al., 2007b; O’Donnell et al., 2005). Finally, functional
studies have directly documented the potent pro- and anti-
tumorigenic activity of specific miRNAs both in vitro and in vivo
(Ventura and Jacks, 2009).
As a consequence of the important functions provided by
miRNAs in cancer cells, potential therapeutic approaches thatCell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc. 1005
target this pathway have recently attracted attention. Although
significant focus in this area has been directed toward anti-
sense-mediated inhibition of oncogenic miRNAs (Love et al.,
2008; Stenvang et al., 2008), several lines of evidence suggest
that miRNA replacement represents an equally viable, if not
more efficacious, strategy. Although specific miRNAs are often
overexpressed in cancer cells, most miRNAs are downregulated
in tumors (Gaur et al., 2007; Lu et al., 2005). Global miRNA
repression enhances cellular transformation and tumorigenesis
in both in vitro and in vivo models (Kumar et al., 2007), under-
scoring the protumorigenic effects of miRNA loss-of-function.
Moreover, we have previously demonstrated that hyperactivity
of Myc, a common occurrence in diverse tumor types, leads to
widespread miRNA repression (Chang et al., 2008). Enforced
expression of individual miRNAs in lymphoma cells transformed
by Myc or other oncogenes dramatically suppresses tumorigen-
esis. These observations suggest that re-expression of even
a single miRNA in tumor cells could provide significant thera-
peutic benefit. Supporting this notion, two recent reports
demonstrated that viral delivery of let-7 miRNAs suppressed
tumor growth in a mouse model of lung adenocarcinoma (Es-
quela-Kerscher et al., 2008; Kumar et al., 2008). Importantly,
let-7 directly targets KRAS, the initiating oncogene in this tumor
model (Johnson et al., 2005). Thus, the utility of miRNAs as more
general anticancer therapeutics in situations where they do not
target the initiating oncogene remains to be studied.
Hepatocellular carcinoma (HCC) is the third-leading cause of
death from cancer and the fifth most common malignancy world-
wide (Roberts, 2008; Thorgeirsson and Grisham, 2002). HCC is
often diagnosed at an advanced stage when it is no longer
amenable to curative therapies. Highly active drug-metabolizing
pathways and multidrug resistance transporter proteins in tumor
cells further diminish the efficacy of current therapeutic regimens
for this cancer type. Alternative approaches are therefore
needed to overcome these barriers to successful therapy. Fortu-
nately, the liver is well-suited for such alternative strategies since
it is easily targeted by both viral and nonviral gene and small-
molecule delivery systems (Alexander et al., 2008; Pathak
et al., 2008). In this regard, gene therapy vectors based on ad-
eno-associated virus (AAV) are particularly promising. Recent
advances in AAV vector technology include a self-complemen-
tary genome that enhances therapeutic gene expression and
nonhuman primate AAV serotypes that facilitate efficient trans-
duction following vascular delivery. Significantly, these improve-
ments allow 90%–100% transduction of hepatocytes and long-
term gene expression without toxicity following a single systemic
administration of recombinant virus (McCarty et al., 2003; Nakai
et al., 2005; Rodino-Klapac et al., 2007; Wang et al., 2003).
Because of their small size, regulatory RNAs are especially
amenable to AAV-mediated delivery.
In this study, we tested the hypothesis that miRNAs can be
used as general anticancer therapeutics through their effects
on tumor cell proliferation and death even when they do not
target the initiating oncogene. We reasoned that the most thera-
peutically useful miRNAs would be expressed at low levels in
tumors but would be highly expressed, and therefore tolerated,
in normal tissues. miR-26a fulfills these criteria, exhibiting high
expression in normal adult liver but low expression in both1006 Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc.human and murine liver tumors. miR-26a directly downregulates
cyclins D2 and E2 and induces a G1 arrest in human liver
cancer cells in vitro. AAV-mediated miR-26a delivery potently
suppresses cancer cell proliferation and activates tumor-
specific apoptosis in vivo, resulting in dramatic suppression of
tumor progression without toxicity. These findings provide
proof-of-concept support for systemic delivery of tumor-sup-
pressing miRNAs as a powerful and highly specific anticancer
therapeutic modality.
RESULTS
Downregulation of Putative Antitumorigenic miRNAs
in Myc-Induced Liver Tumors
We previously demonstrated that Myc activation in B cell
lymphoma models results in downregulation of a large cohort
of miRNAs, including miR-15a/16, miR-26a, miR-34a, miR-150,
and miR-195 (Chang et al., 2008). Enforced expression of these
specific miRNAs dramatically inhibits B cell lymphomagenesis.
To extend these findings to a solid tumor model and to investi-
gate the potential use of these miRNAs as anticancer therapeu-
tics, we studied their expression in a previously described model
of liver cancer in which mice harboring a tetracycline (tet)–
repressible MYC transgene (tet-o-MYC) are crossed with mice
expressing the tet-transactivator protein (tTA) driven by the liver
activator promoter (LAP) (Beer et al., 2004; Felsher and Bishop,
1999; Shachaf et al., 2004). Upon removal of doxycycline (dox),
bi-transgenic animals express MYC specifically in the liver and
subsequently develop liver tumors resembling HCC with
complete penetrance.
We sought miRNAs that are highly expressed and therefore
tolerated in normal tissues but are expressed at reduced levels
in tumors. Such miRNAs might exhibit antiproliferative and pro-
apoptotic effects that are restricted to cancer cells. Northern blot-
ting revealed that miR-26a, and to a lesser extent miR-15a and
miR-16, fulfilled these criteria, exhibiting high expression in
normal liver from adult mice lacking the LAP-tTA transgene
(harboring an inactive tet-o-MYC transgene) but low expression
in liver tumors from tet-o-MYC, LAP-tTA bi-transgenic animals
(Figure 1A). Notably, these miRNAs did not exhibit reduced
expression in normal-appearing liver from bi-transgenic animals,
consistent with the previous demonstration that Myc levels are
only minimally increased in nontumor tissue in these mice
(Shachaf et al., 2004). Additional miRNAs with antitumorigenic
activity in B lymphoma cells were expressed at approximately
equivalent levels in normal liver and tumors (miR-195, Figure 1A)
or were not detectable in these tissues (miR-150,data not shown).
miR-34a was strongly upregulated in liver tumors (Figure 1A),
perhaps reflecting its regulation by p53, which is retained and
active in some tumors in these animals (Beer et al., 2004; He
et al., 2007b). As expected, miR-17 was expressed at high levels
in liver tumors, consistent with our previous demonstration that
the miR-17-92 cluster is directly transactivated by Myc (O’Donnell
et al., 2005).
Because miR-26a exhibited the most dramatic downregula-
tion in liver tumors in bi-transgenic animals, we further examined
its expression in a panel of human HCC samples. Consistent with
the mouse tumor data, miR-26a was expressed at statistically
Figure 1. Dysregulated Expression of miRNAs in Mouse and Human Liver Tumors
(A) Northern blot analysis of miRNA expression in normal liver (N) or tumor tissue (T) from mice of the indicated genotypes. Graphs depict relative quantification of
miRNA levels normalized to tRNALys abundance.
(B) qPCR analysis of miR-26a expression in human HCC and normal liver biopsies. miRNA abundance was normalized to 18S rRNA expression. p value calcu-
lated by two-tailed t test.
(C) miR-26a expression in individual HCC tumors relative to expression in paired normal liver samples.significantly lower levels in human tumors compared to normal
human liver tissue (Figure 1B). Paired normal liver biopsy mate-
rial was available for a subset of the HCC samples. Seven of
eight of these samples showed reduced miR-26a expression
relative to the associated normal liver control (Figure 1C). On
the basis of these results from human and mouse liver tumors,
we selected miR-26a for functional studies to evaluate its anti-
tumorigenic properties and potential therapeutic utility for liver
cancer in vitro and in vivo.
miR-26a Expression Induces a G1 Arrest in Human Liver
Cancer Cells
As an initial test of the antiproliferative properties of miR-26a in
liver cancer cells, we utilized a murine stem cell virus (MSCV)–
derived retroviral construct to enforce expression of this miRNA
in HepG2 cells. As controls for this experiment, we used viruses
that express miR-18a, a component of the protumorigenic
miR-17-92 cluster, and miR-34a, which is known to have potent
antiproliferative and proapoptotic activity in other cell lines(Bommer et al., 2007; Chang et al., 2007; He et al., 2007a;
Raver-Shapira et al., 2007; Tarasov et al., 2007). Northern blot-
ting demonstrated that miR-26a expression levels in HepG2 cells
closely mirror expression levels in tumors from tet-o-MYC; LAP-
tTA animals (Figure 2A). Infection with MSCV-miR-26a results in
enforced expression of this miRNA at a level comparable to that
observed in normal liver tissue. Flow cytometric analysis of retro-
virally infected cell populations revealed fewer cells in S phase
and increased numbers of cells in G1 following infection with
MSCV-miR-26a or MSCV-miR-34a, compared with cells in-
fected with MSCV-empty or MSCV-miR-18a, suggesting that
miR-26a and miR-34a induce a G1 arrest (Figure 2B). To more
accurately quantify the numbers of cells arrested in G1, we
treated cells with the microtubule-destabilizing agent nocoda-
zole, which traps cycling cells in M phase. Cell populations
with enforced miR-26a or miR-34a expression were character-
ized by significantly increased numbers of cells remaining in G1
(Figure 2C), confirming that these miRNAs arrest the cell cycle
at this stage.Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc. 1007
Figure 2. miR-26a Induces a G1 Arrest in Human Hepatocellular Carcinoma Cells
(A) Northern blots documenting miRNA expression levels in normal liver and tumors from tet-o-MYC; LAP-tTA mice and in uninfected or retrovirally infected
HepG2 cells. tRNALys served as a loading control.
(B) Cell-cycle profiles of retrovirally infected HepG2 cells as determined by propidium-iodide (PI) staining and flow cytometry. Numbers over each histogram indi-
cate the percentage of cells in G1, S, and G2/M cell-cycle phases.
(C) Cell-cycle profiles of retrovirally infected HepG2 cells following treatment with nocodazole (Noc). Numbers over each histogram indicate the percentage of
cells remaining in G1.miR-26a Directly Represses Expression of Cyclin D2
and Cyclin E2
To investigate the mechanisms through which miR-26a induces
a G1 cell-cycle arrest, we examined predicted targets of this
miRNA using the Targetscan algorithm (Grimson et al., 2007).
This analysis predicts that miR-26a regulates cyclin E1
(CCNE1), cyclin E2 (CCNE2), cyclin D2 (CCND2), and cyclin-
dependent kinase 6 (CDK6), all of which play a critical role in tran-
sition through the G1-S checkpoint (Vermeulen et al., 2003).
Western blotting was used to determine whether miR-26a
represses any of these putative targets in retrovirally infected
cell populations. Although infection with MSCV-miR-26a did
not affect the abundance of cyclin E1 and CDK6 (data not
shown), significantly reduced levels of cyclin D2 and cyclin E2
were observed in cells with enforced miR-26a expression
(Figures 3A and 3B).
Both CCND2 and CCNE2 have single predicted binding sites
in their 30 UTRs that are highly conserved in mammals and, in
the case of CCND2, present in chicken (Figures 3C and 3D).
To verify that these transcripts are directly regulated by miR-
26a, reporter plasmids were constructed in which portions of
the 30 UTRs encompassing the predicted binding sites, with or
without mutations that would disrupt miRNA interaction, were
cloned downstream of a luciferase open reading frame. When
introduced into HepG2 cells, constructs with intact miR-26a
binding sites were expressed at significantly lower levels than
the mutant constructs, consistent with direct functional interac-
tion of endogenously expressed miR-26a with these sites1008 Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc.(Figures 3E and 3F). Cotransfection of reporter plasmids with
a synthetic miR-26a mimic further repressed luciferase activity
produced from wild-type, but not mutant, reporter constructs.
Demonstrating the specificity of these effects, cotransfection
with a miR-18a mimic actually diminished downregulation of
the wild-type reporters, possibly by competing for limiting
miRNA pathway components and thereby relieving the transcript
from repression. These data document that miR-26a directly
represses expression of cyclin D2 and cyclin E2, providing one
mechanism through which this miRNA arrests cell-cycle
progression.
MYC Is Not a Target of miR-26a
Having demonstrated that miR-26a potently arrests proliferation
of hepatocellular carcinoma cells in vitro, we next initiated
a series of experiments to assess whether systemic delivery of
this miRNA could be used as a therapeutic strategy for this tumor
type in vivo. The tet-o-MYC; LAP-tTA liver cancer model repre-
sents an ideal setting for these studies. Because these mice
were constructed with a human MYC transgene that includes
its 30 UTR (Felsher and Bishop, 1999), we first confirmed that
miR-26a does not regulate MYC itself. MYC is not a predicted
target of miR-26a according to several commonly used algo-
rithms including Targetscan, miRanda, and PicTar (Betel et al.,
2008; Grimson et al., 2007; Krek et al., 2005). Manual inspection
of the human MYC 30 UTR further documents the absence of
even a minimal hexamer complementary to the miR-26a seed
sequence. Western blotting confirms that retroviral expression
Figure 3. miR-26a Negatively Regulates Cyclins D2 and E2
(A and B) Western blots documenting abundance of cyclins D2 and E2 in retrovirally infected HepG2 cells. Relative quantification of band intensities, normalized
to tubulin levels, are shown below blots.
(C and D) Sequence and evolutionary conservation of the miR-26a binding sites in the 30 UTRs of transcripts encoding cyclin D2 (CCND2) and cyclin E2 (CCNE2).
Mutations introduced into luciferase reporter constructs are shown in red.
(E and F) Relative firefly luciferase activity derived from CCND2 (E) and CCNE2 (F) 30 UTR reporter constructs following transfection into HepG2 cells alone or in
combination with miR-18a or miR-26a synthetic miRNA mimics. All values were normalized to renilla luciferase activity produced from a cotransfected control
plasmid. Error bars represent standard deviations from 3 independent transfections. *p < 0.05; **p < 0.01 (two-tailed t test).of miR-26a in HepG2 cells does not affect Myc protein abun-
dance (see Figure S1 available online). Thus, miR-26a does not
target the initiating oncogene in tet-o-MYC; LAP-tTA mice, sup-
porting the use of this model for assessing the general tumor
suppressing properties of miR-26a in vivo.
Development of an AAV Vector System
to Simultaneously Express a miRNA and eGFP
The development of self-complementary AAV (scAAV) vectors
and the availability of AAV serotypes for improved transduction
of specific target tissues has expanded the usefulness of this
virus for therapeutic gene delivery (Gao et al., 2002; McCarty,
2008; McCarty et al., 2003; Nakai et al., 2005; Wang et al.,
2003). In particular, these advances allow highly efficient trans-
duction of hepatocytes following systemic administration of
scAAV8 vectors. We therefore constructed a scAAV vectorsystem to evaluate the therapeutic potential of miR-26a in tet-
o-MYC; LAP-tTA mice. To allow facile assessment of target
tissue transduction, the vector included enhanced green fluores-
cent protein (eGFP) driven by the ubiquitously expressed elon-
gation factor 1 alpha (EF1a) promoter. Moreover, since miRNAs
are frequently embedded within introns of both protein-coding
and noncoding primary transcripts, we cloned miR-26a into the
short intron that is part of the EF1a promoter unit (Wakabaya-
shi-Ito and Nagata, 1994), thus allowing simultaneous produc-
tion of eGFP and miR-26a from a single transcript (scAAV.
miR26a.eGFP; Figure 4A). We confirmed that this vector effi-
ciently expresses both miR-26a and eGFP by transient transfec-
tion of HeLa cells. Northern blotting demonstrated that the
scAAV.miR26a.eGFP vector produced an equivalent amount
of mature miRNA as a control vector in which the miRNA was
in an exonic context (scAAV.miR26a; Figures 4A and 4B).Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc. 1009
Figure 4. Development of an AAV Vector System to Simultaneously Express a miRNA and eGFP
(A) Schematic representation of scAAV vectors used in this study depicting locations of inverted terminal repeats (ITRs), elongation factor 1 a promoter (EF1a),
miRNA (shown in hairpin form), and enhanced green fluorescent protein (eGFP) open reading frame.
(B) Northern blot of transiently transfected HeLa cells demonstrating equivalent levels of miR-26a when expressed from an intronic (scAAV.miR26a.eGFP) or
exonic (scAAV.miR26a) context. Cotransfection with a miR-122a expression plasmid (pcDNA-miR-122a) provided a control for transfection efficiency while
tRNALys levels documented equal loading.
(C) Fluorescent microscopy showing eGFP expression in HeLa cells transiently transfected with the indicated AAV vectors.
(D) Northern blots showing expression of miRNAs in livers 21 days following administration of the indicated AAV vectors.
(E) Fluorescent microscopy showing efficient transduction of hepatocytes, as indicated by eGFP expression, 21 days following AAV administration.Fluorescent microscopy of transfected cells similarly docu-
mented equivalent eGFP expression from scAAV.miR26a.eGFP
and a control vector lacking intronic miR-26a sequences (scAAV.
eGFP; Figures 4A and 4C).
scAAV.eGFP and scAAV.miR26a.eGFP were then packaged
with the AAV8 serotype for in vivo delivery. 1 3 1012 vector
genomes (vg) per animal were administered with a single tail-
vein injection, and liver tissue was harvested three weeks later
for analysis of miRNA and eGFP expression. As expected,
mice transduced with scAAV8.miR26a.eGFP exhibited high-
level expression of miR-26a in the liver (Figure 4D). Fluorescent
microscopy documented over 90% transduction of hepatocytes
with both vectors (Figure 4E). Importantly, it has previously been
demonstrated that AAV8-mediated delivery of some short-
hairpin RNA (shRNA) constructs induces acute liver toxicity1010 Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc.due to competitive inhibition of the miRNA pathway (Grimm
et al., 2006). scAAV8.miR26a.eGFP administration does not
cause these effects, as demonstrated by normal levels of endog-
enously expressed miRNAs in transduced livers (Figure 4D); an
absence of any acute inflammation, fibrosis, or overt histologic
evidence of toxicity (Figure S2); and maintenance of normal
levels of serum markers of liver function (ALT, AST, alkaline
phosphatase, and total and direct bilirubin) (Table S1). These
data demonstrate that scAAV8 provides an effective, nontoxic
means to deliver miRNAs to the liver.
Therapeutic Delivery of miR-26a Suppresses
Tumorigenesis in tet-o-MYC; LAP-tTA Mice
To assess the therapeutic efficacy of miR-26a delivery for
liver cancer, we administered scAAV8.miR26a.eGFP, or
Figure 5. AAV-Mediated miR-26a Delivery Suppresses Tumorigenesis in tet-o-MYC; LAP-tTA Mice
(A) Timeline of miR-26a therapeutic delivery experiment.
(B) Gross tumor burden of livers from miR-26a-treated and control animals, as determined by quantification of tumor area using the ImageJ software package.
The mean tumor burden in each treatment group is indicated by horizontal lines. Data points highlighted by asterisks represent animals that exhibited low AAV
transduction efficiency (see Figure S5). p value calculated by two-tailed t test.
(C) Representative images of livers from miR-26a-treated and control animals.
(D) Liver-to-body weight ratios of miR-26a-treated and control animals. A chi-square statistic was used to compare the fraction of animals in each treatment
group with a liver-to-body weight ratio above 0.1 (indicated by horizontal line). Data points highlighted by asterisks represent animals that exhibited low AAV
transduction efficiency (see Figure S5).scAAV8.eGFP as a negative control, to tumor-bearing tet-o-
MYC; LAP-tTA mice. Animals were taken off dox at 4 weeks of
age, and virus was administered at 11 weeks of age, a time point
at which animals typically have multiple small to medium sized
tumors (Figures 5A and S3). Three weeks later, animals were
sacrificed and tumor burden was assessed. Six out of eight
mice treated with control virus developed fulminant disease in
which the majority of liver tissue was replaced with tumor tissue
(Figures 5B, 5C, S4). In contrast, 8 of 10 scAAV8.miR26a.eGFP-
treated animals were dramatically protected, exhibiting only
small tumors or a complete absence of tumors upon gross
inspection (Figure 5B, p < 0.05). Liver-to-body weight ratios
were significantly lower in scAAV8.miR-26a.eGFP-treated
animals compared to scAAV8.eGFP-treated animals (p < 0.05),
further documenting tumor suppression (Figure 5D).
Aggressive liver tumors arose in 2 of 10 scAAV8.miR26a.
eGFP-treated mice. To investigate the cause of these treatmentfailures, we assessed AAV transduction efficiency by scoring
GFP-positive hepatocytes and by quantifying transduced vector
genomes by quantitative real-time PCR (qPCR). Interestingly,
these mice exhibited significantly lower transduction efficiency
than the successfully treated animals (Figure S5). This strongly
suggests that the development of disease in these animals
was a result of technical failure rather than biologic resistance
to miR-26a-mediated tumor suppression. We conclude that effi-
cient transduction of hepatocytes with scAAV8.miR26a.eGFP
uniformly diminished disease progression in this model.
Delivery of miR-26a Reduces Cancer Cell Proliferation
and Induces Tumor-Specific Apoptosis
To ascertain the cellular mechanisms underlying miR-26a-
mediated tumor suppression, we first confirmed that scAAV8.
miR26a.eGFP effectively delivered the miRNA to tumor cells.
qPCR was used to measure miR-26a expression in tumors 5 orCell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc. 1011
Figure 6. AAV-Mediated Transduction of Tumor Cells in tet-o-MYC; LAP-tTA Mice
(A) Expression of miR-26a in tumors in AAV-transduced animals. qPCR was used to measure miRNA abundance in tumors 5 or 10 days following administration of
scAAV8.eGFP (eGFP) or scAAV8.miR26a.eGFP (miR26a.eGFP). All values were normalized to 18S rRNA expression. Normal liver expression and tumor expres-
sion lines were derived from qPCR analysis of miR-26a levels in samples shown in Figure 1A. Each box represents the range of expression observed. The ends of
the boxes represent the 25th and 75th percentiles, the bars indicate the 10th and 90th percentiles, and the median is depicted by a horizontal line within the boxes.
(B) Fluorescence microscopy of tumor sections demonstrating GFP expression in tumor cells in AAV-transduced animals.10 days after vector administration (dox off at 4 weeks, virus
administered at 11 weeks; 21–30 tumors analyzed per treatment
condition). These studies revealed restoration of physiologic
miR-26a expression in scAAV8.miR26a.eGFP-treated tumors,
whereas miRNA levels were unchanged following administration
of scAAV8.eGFP (Figure 6A). Fluorescence microscopy also
documented GFP expression in tumor cells, further demon-
strating AAV transduction (Figure 6B).
We next examined cellular proliferation in liver tissue 5, 10, and
21 days following vector administration. Ki67 staining revealed
rapid proliferation of tumor cells at all time points in scAAV8.
eGFP-treated animals (Figures 7A, 7B, S6, and S7). Consistent
with our earlier demonstration that expression of miR-26a
arrests the cell cycle in HepG2 cells, we observed markedly
reduced Ki67 staining in tumors following administration of
scAAV8.miR26a.eGFP. No difference in Ki67 staining of non-
tumor tissue was apparent between the treatment groups,
although baseline Ki67 signal was low in normal liver reflecting
the slow proliferative rate of adult hepatocytes.
Treatment-induced apoptosis was also assessed by TUNEL
staining. Apoptotic cells were rare in normal liver tissue and
present at low levels in tumors from scAAV8.eGFP-treated
animals at all time points (Figures 7C, 7D, S6, and S7). Remark-
ably, AAV-mediated delivery of miR-26a potently induced
apoptosis specifically in tumor cells without measurably causing
death of normal hepatocytes. These data are consistent with our
earlier findings that scAAV8.miR26a.eGFP administration
caused no measurable liver toxicity in normal animals (Figure S2
and Table S1). To further investigate the specificity of miR-26a-
induced apoptosis, we performed TUNEL staining on a broader
panel of tissues including those with high proliferative indices
(testis and spleen) and low proliferative indices (heart, lung,
kidney, and pancreas) (Figure S8). scAAV8.miR26a.eGFP
administration did not cause a measurable increase in the1012 Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc.frequency of apoptotic cells in any of these tissues. Together
with the Ki67 data, these results document that miR-26a-medi-
ated tumor suppression is associated with rapid and sustained
inhibition of cancer cell proliferation and highly specific induction
of tumor cell death.
DISCUSSION
Since the initial discovery of a functional RNA interference (RNAi)
system in mammals, significant effort has been devoted to the
development of therapeutics that utilize this pathway (de Fou-
gerolles et al., 2007). While progress has been made toward
the design and delivery of short interfering (si) and short hairpin
(sh) RNAs for therapeutic gene silencing, accumulating evidence
indicates that modulation of miRNA activity also represents an
attractive strategy. miRNAs potently influence cellular behavior
through the regulation of extensive gene expression networks
(Baek et al., 2008; Selbach et al., 2008). Therapeutic modulation
of a single miRNA may therefore affect many pathways simulta-
neously to achieve clinical benefit. Thus far, most translational
in vivo studies targeting miRNAs have aimed to inhibit miRNA
function through the use of antisense reagents, such as antago-
mirs, locked nucleic acid (LNA) oligomers, and other modified
oligonucleotides (Elmen et al., 2008; Esau et al., 2006; Krutzfeldt
et al., 2005). While the in vivo use of synthetic oligonucleotide
inhibitors is promising and will no doubt remain a fruitful area
of investigation, the therapeutic delivery of miRNAs has certain
advantages, especially in cancer. It has been demonstrated
that most tumors are characterized by globally diminished
miRNA expression (Gaur et al., 2007; Lu et al., 2005) and that
experimental impairment of miRNA processing enhances
cellular transformation and tumorigenesis (Kumar et al., 2007).
Additionally, common oncogenic lesions can result in wide-
spread miRNA repression (Chang et al., 2008). Thus, miRNA
Figure 7. miR-26a Delivery Induces Tumor-Specific Cell-Cycle Arrest and Apoptosis
(A) Representative DAPI and Ki67-stained sections from miR-26a-treated and control tet-o-MYC; LAP-tTA animals 5 days after AAV administration showing
tumors (outlined with dotted line) and adjacent normal-appearing liver.
(B) Quantification of Ki67 staining in tumors from miR-26a-treated and control animals. Olympus Slidebook 4.2 was used to quantify the Ki67 fluorescence inten-
sity in tumors in 3–5 randomly chosen fields per animal (n = 2–4 animals per treatment per time point). The mean Ki67 fluorescence intensity per condition is
plotted with error bars representing standard deviations.
(C) Representative DAPI and TUNEL-stained sections from miR-26a-treated and control animals 5 days after AAV administration. Tumors are outlined with dotted
lines.
(D) Quantification of TUNEL staining in tumors from miR-26a-treated and control animals. ImageJ was used to quantify the TUNEL-positive area in tumors in six
randomly chosen fields per animal (n = 2–4 animals per treatment per time point). The mean TUNEL-positive area per condition is plotted with error bars repre-
senting standard deviations.delivery might allow the therapeutic restitution of physiological
programs of regulation lost in cancer and other disease states.
Therapeutic miRNA delivery may have unique technical
advantages as well. First, the risk of off-target gene silencing is
likely to be lower than that associated with artificial RNAi triggers
since physiologic gene expression networks have evolved to
accommodate the regulatory effects of endogenous miRNAs.
Second, compared with siRNAs or shRNAs that target a single
transcript, the regulation of hundreds of targets in multiple path-
ways by miRNAs may reduce the emergence of resistant clones
in diseases such as cancer, since many simultaneous mutations
would be required to subvert the effects of miRNA expression. At
the same time, however, miRNA-based therapies will require
thorough preclinical validation as these broad effects may, in
some cases, have toxic consequences. Finally, it has been previ-
ously shown that the miRNA biogenesis pathway can becompetitively inhibited by the expression of certain shRNAs, re-
sulting in toxic effects following delivery of these transcripts
(Grimm et al., 2006). This may be due to inefficient processing
and/or nuclear-cytoplasmic transport of shRNA sequences
that are not evolutionarily adapted for precise handling by this
pathway. Supporting this notion, shRNA-associated toxicity
can be mitigated by placing a shRNA into an miRNA-like context
(McBride et al., 2008). In this study, we demonstrated high
expression of an exogenously supplied natural miRNA without
toxic effects on endogenous miRNA biogenesis.
The results described herein demonstrate that therapeutic
delivery of a miRNA can result in tumor suppression even in
a setting where the initiating oncogene is not targeted. This
establishes the principle that miRNAs may be useful as anti-
cancer agents through their ability to broadly regulate cancer
cell proliferation and survival. Furthermore, this study designCell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc. 1013
involved the treatment of existing tumors with a miRNA, a para-
digm closely related to the clinical scenarios in which such ther-
apies would be employed. Finally, we demonstrated highly
specific effects of miRNA delivery on tumor cells without
affecting surrounding normal tissue. Although the molecular
basis of this specificity requires further investigation, it is likely
that the high physiologic expression of miR-26a in normal hepa-
tocytes confers tolerance to exogenous administration of this
miRNA. In contrast, the specific reduction of miR-26a in
neoplastic cells and their sensitivity to its restored expression
underscores the contribution of loss-of-function of this miRNA
to tumorigenesis in this setting. It is noteworthy that large-scale
cloning efforts have documented expression of miR-26a in most
mouse and human tissues (Landgraf et al., 2007), while in situ
hybridization data from zebrafish have documented ubiquitous
expression with especially high levels in the head, spinal cord,
and gut (Wienholds et al., 2005). The widespread expression of
this miRNA is consistent with our observation that systemic
AAV-mediated delivery of miR-26a is well tolerated by many
tissues. Overall, our demonstration that miR-26a delivery
potently suppresses even a severe, multifocal model of carcino-
genesis in the absence of measurable toxicity provides proof-of-
principle that the systemic administration of miRNAs may be
a clinically viable anticancer therapeutic strategy.
In this study, we elected to use an AAV-based vector system,
an especially attractive platform for regulatory RNA delivery (Gier-
ing et al., 2008; Grimm and Kay, 2007; McCarty, 2008). When
delivered in viral vectors, miRNAs are continually transcribed,
allowing sustained high level expression in target tissues. The use
of tissue-specific promoters could restrict this expression to
particular cell types of interest. Compared with retroviral delivery
systems, DNA viruses such as AAV carry substantially diminished
risk of insertional mutagenesis since viral genomes persist
primarily as episomes (Schnepp et al., 2003). Furthermore, the
availability of multiple AAV serotypes allows efficient targeting
of many tissues of interest (Gao et al., 2002; McCarty, 2008).
Finally, the general safety of AAV has been well documented,
with clinical trials using this platform already under way (Carter,
2005; Maguire et al., 2008; Park et al., 2008). Despite these
advantages, prior studies have achieved mixed results when at-
tempting to use AAV vectors to transduce HCC cells in vivo
(Peng et al., 2000; Shen et al., 2008). Our successful use of AAV
to treat an animal model of HCC may indicate that tumor cells
are highly sensitive to restored expression of miRNAs, resulting
in strong tumor suppression even with a relatively low number
of vector genomes introduced into each cell. The use of self-
complementary vectors may have further enhanced tumor cell
transduction and therapeutic miRNA expression in the present
study. Finally, while our findings are most consistent with miR-
26a influencing cancer cell proliferation and survival through
a cell-autonomous mechanism, transduction of tumor-associ-
ated stromal cells may have also contributed to the observed
therapeutic effects through a yet unknown mechanism.
We have previously documented that miR-26 family members
suppress tumorigenesis in c-Myc-driven B lymphoma cells
(Chang et al., 2008) and now extend these findings to the tet-
o-MYC; LAP-tTA HCC model. Our demonstration that a geneti-
cally complex human liver cancer cell line is also susceptible to1014 Cell 137, 1005–1017, June 12, 2009 ª2009 Elsevier Inc.miR-26a-mediated antiproliferative effects suggests that the
tumor suppressive activities of this miRNA are not limited to
Myc-initiated malignancies. Several additional lines of evidence
further support this notion. Work from our group and others has
revealed a role for miR-26a in the p53 tumor suppressor network
as this miRNA is upregulated in a p53-dependent manner
following DNA damage (Chang et al., 2007; Xi et al., 2006). Addi-
tionally, a profiling study of human anaplastic thyroid cancers
(ATC) identified miR-26a as consistently downregulated and
demonstrated that transient transfection of this miRNA signifi-
cantly impairs proliferation of ATC cells in vitro (Visone et al.,
2007). Moreover, the miR-26a-1-encoding locus at 3p21.3 is
contained within a submegabase interval that is frequently
deleted in small cell lung carcinomas, renal cell carcinomas,
and breast carcinomas (Kashuba et al., 2004). These observa-
tions suggest broad antitumorigenic properties of miR-26 family
members in diverse settings. Nevertheless, if future work reveals
that the effectiveness of miR-26 delivery is restricted to settings
of Myc dysregulation, therapeutic delivery of this miRNA may still
be beneficial for a large number of cancer subtypes since hyper-
activity of Myc is one of the most common attributes of human
cancer cells.
Although miR-26a delivery confers dramatic tumor protection,
it is likely that many equally or more effective miRNAs with ther-
apeutic potential remain to be functionally characterized. The
approach employed in this study provides an experimental
framework to identify additional favorable candidates. We
suggest that the most promising miRNAs will, like miR-26a, be
highly expressed in a wide variety of normal tissues, be underex-
pressed in the disease state being studied, and, when evaluated
using in vitro or in vivo models, demonstrate specific phenotypic
effects in disease cells while sparing normal cells. While there
clearly remains significant work to be done both in identifying
such miRNAs and optimizing their controlled delivery, our find-
ings highlight the therapeutic promise of this approach.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293, HEK293T, and HeLa cells were cultured in high glucose (4.5 g/l)
DMEM supplemented with 10% fetal bovine serum (FBS), penicillin, and strep-
tomycin. HepG2 cells were cultured in EMEM supplemented with 10% FBS,
penicillin, and streptomycin.
RNA Isolation, Northern Blotting, and qPCR
Total RNA was isolated from cultured cells or tissue using Trizol (Invitrogen) ac-
cording to the manufacturer’s protocol. Northern blotting was performed as
previously described (Hwang et al., 2007) using Ultrahyb-oligo buffer (Ambion)
and oligonucleotide probes perfectly complementary to the mature miRNA
sequences. All membranes were stripped and reprobed for tRNALys as
a loading control. qPCR for miR-26a and 18S rRNA was performed using pre-
designed Taqman primers and probes (ABI) according to manufacturer’s
instructions.
Cell-Cycle Profiling
Retrovirally infected HepG2 cells (5 3 105) were plated after selection; 24 hr
later, cells were harvested for analysis by propidium iodide (PI) staining and
flow cytometry as described previously (Hwang et al., 2007). For M-phase
trapping experiments, 100 ng/ml nocodazole was added for 24 hr prior to
harvesting floating and adherent cells for PI staining.
Western Blotting
Antibodies for immunoblotting were as follows: anti-c-Myc mouse monoclonal
(clone 9E10; Zymed), anti-cyclin E1 rabbit polyclonal (Abcam), anti-cyclin E2
rabbit polyclonal (Cell Signaling), anti-cyclin D2 rabbit polyclonal (Cell
Signaling), anti-CDK6 mouse monoclonal (clone DCS83; Cell Signaling), and
anti-a-tubulin mouse monoclonal (clone DM1A; Calbiochem).
Luciferase Reporter Assays
HepG2 cells (2.5 3 105) were plated in triplicate wells of a 24-well plate and
transfected 16 hr later with 100 ng of the indicated pGL3 30 UTR reporter
construct and 5 ng of phRL-SV40 (Promega) using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions. Where indicated, miR-
18a or miR-26a mimics (Dharmacon) were cotransfected at 25 nM final
concentration; 24 hr after transfection, cells were lysed and assayed for firefly
and renilla luciferase activity using the Dual-Luciferase Reporter Assay System
(Promega). Firefly luciferase activity was normalized to renilla luciferase
activity for each transfected well. Data depicted are representative of three
independent experiments performed on different days.
Vector Delivery
Tet-o-MYC; LAP-tTA mice were maintained on dox-containing food (100 mg/
kg) until 4 weeks of age. At 11 weeks of age, AAV was administered at a dose of
1012 vg per animal by tail vein injection (200 ml total volume) using a 30 gauge
ultra-fine insulin syringe. The Research Institute at Nationwide Children’s
Hospital Animal Care and Use Committee approved all housing and surgical
procedures.
Analysis of Liver Function Tests
Four month old C57/BL10 mice (n = 5) were dosed with 1012 vg of scAAV8.
miR26a.eGFP by tail vein injection. Blood was collected prior to vector admin-
istration and at 3 weeks post-injection from the submandibular vein. Serum
analysis was performed by Ani Lytics (Gaithersburg, MD).
Immunohistochemistry
Tissues were collected in 10% buffered formalin, embedded in paraffin, and
stained in hematoxylin and eosin following standard procedures. For Ki67
detection, slides were microwaved for 15 min in 10 mM sodium citrate
(pH 6.0), cooled for 20 min at 25C, and washed three times (5 min each)
with PBST (PBS, 0.1% Tween 20). The tissue was permeabilized by incubating
the slides in 1% Triton X-100 in PBS at 4C for 30 min and then washed again
three times in PBST. After blocking for 1 hr at 25C in blocking buffer (PBS con-
taining 10% goat serum and 0.2% Triton X-100), slides were incubated over-
night in a humidity chamber with a mouse anti-human Ki67 monoclonal anti-
body (BD Biosciences) diluted 1:100 in blocking buffer. Following another
three PBST washes, slides were incubated with Alexa 594-conjugated goat
anti-mouse secondary antibody at a 1:200 dilution (Molecular Probes). Slides
were washed and nuclei counterstained with DAPI. The intensity of the Ki67
signal was quantified using the Olympus Slidebook 4.2 software. TUNEL stain-
ing was performed with the TMR Red In situ cell death detection kit (Roche)
according to manufacturer’s instructions. Quantification of TUNEL-positive
area was performed using ImageJ software. For GFP visualization, tissues
were fixed in 4% paraformaldehyde followed by an overnight incubation in
30% sucrose incubation and then embedded in OCT compound.
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